Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.
Scope
Comprehensive analysis of the cardiovascular market by disease area in each of the seven major markets
An assessment of trends within the cardiovascular market between 2003 and 2006.
Intellectual Property risk assessment for Top 10 brands in each market.
Forecast models for key brands, active agents and pipeline products up to 2016.
Report Highlights The cardiovascular market in the seven major markets is a mature market with negligible sales growth between 2006 and 2016. Growth of SU sold in the cardiovascular market is expected to increase by 3%, driven by population growth, leaving an effective cardiovascular sales growth of -3%.
Use of generics will increase as key products lose patent protection and healthcare providers push for greater cost containment. Patent expiries during the pivotal 2010-13 window expose $30.9 billion worth of branded drugs to generic competition.
Cardiovascular pipeline products are unlikely to make a significant impact on the market with only 16% ($11.9 billion) of 2016 sales generated from the current pipeline. A number of blockbuster products are likely to be launched but the sales are likely to be greatly reduced from the levels seen in 2006.
Reasons to Purchase
Understand market specific drivers and predict the future potential of key cardiovascular brands
Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
Consider, assess and react to opportunities and risks influencing the leading cardiovascular brands
Other users found this report page using the following search terms:
cardiovasculargenerics
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
